The Cavallazzi family and Natix are pleased to announce the signing of an agreement formalizing the acquisition of a majority stake in Terhormon by Natix.
With this agreement, Natix increases its historical shareholding to become the majority shareholder, while Mr Umberto Cavallazzi remains both shareholder and CEO, ensuring continuity in leadership, expertise, and a strong connection with the company’s heritage.
This transaction represents a decisive step forward in securing the long-term continuity and growth of Terhormon after a challenging period.
Over the past year, Terhormon has undergone a profound transformation. Following significant investments in infrastructure, process upgrades, and quality systems, the Italian authorities have reviewed and renewed the company’s EU-GMP authorization.
Today, Terhormon operates as a state-of-the-art, EU-based, facility, equipped with a high-standard Quality Management System (QMS) and modernized production lines. The site is now fully ready to supply EU-made, GMP-grade pancreatin API for the most demanding pharmaceutical applications.
Natix, a specialist in natural and bioactive ingredients for food, nutraceutical, and pharmaceutical applications, is part of the Floridienne Group, listed on Euronext Brussels. The acquisition of Terhormon strengthens Natix’s position in the pharma enzyme segment, alongside its established operations in GMP grade papain, bromelain, trypsin, and pancrelipase.
#pharma
#pharmainnovation
#pharmatech
#biotech
